1 Caponigro F, French RC, Kaye SB. Protein kinase C. aworthwhile target for anticancer drugs? Anti Cancer Drugs, 1997; 8: 26
2 Gomez DE, Skilton G, Alonso DF, Kazanietz MG. The role of protein kinase C and novel phorbol ester receptorsin tumor cell invasion and metastasis. Oncol Rep 1999; 6: 1363
3 Jarvis WD, Grant S. Protein kinase C targeting in antineoplastic treatment strategies. Invest New Drugs, 1999; 17: 227
4 Mizuno K, Saido TC, Ohno S, et al. Staurosporine- relatedcompounds, K 252a and UCN-01, inhibit both cPKC andnPKC. FEBS Lett, 1993; 330: 114
5 Seynaeve CM, Kazanietz MG, Blumberg PM, et al. Differentialinhibition of protein kinase C isozymes by UCN-01 a staurosporine analogue. Mol Pharmacol, 1994; 45: 1207
6 Mizuno K, Noda K, Ueda Y, et al. UCN-01, an antitumor drug, is a selective inhibitor of the conventional PKC subfamily. FEBS Lett, 1995 359: 259
7 Shao RG, Cao CX, Pommier Y. Activation of PKC-alpha downstream from caspases during apoptosis in-ducedby 7-hydroxystaurosporine or the topoisomerase inhibitors, camptothecin and etoposide, in hum an myeloid leukemia HL60 cells. J Biol Chem, 1997; 272: 31321
8 T akahashi I, Kobayashi E, Asano K, et al. UCN-01, a selective inhibitor of protein kinase C from Strep- tomyces. J Antibiot (Tokyo), 1987; 40: 1782
9 Takahashi I, Saitoh Y, Yoshifk M, et al. UCN-01 and UCN-02, new selective inhibitors of protein kinase C II. Purification, physico-.hemical properties, structural determination and biological activeties. J Antibiot (Tokyo), 1989; 42: 571
10 Takahashi I, Asano K, Kawamoto I, et al. UCN-01 and UCN-02, new selective inhibitors of protein kinase C I. Screening, producing org an is m and fer-mentation. Antibiot (Tokyo), 1989; 42: 564
11 Takahashi I, Kobayashi E, N akano H, et al. Potent selective inhibition of 7-O-methyl UCN-01 against protein kinase C. J Pharmacol Exp Ther, 1990; 255: 1218
12 Fuse E, Tanii H, Kurata N, et al.Unpredicted clinical pharmacology of UCN - 01 caused by specific binding to human alpha1-acid glycoprotein. Cancer Res, 1998; 58: 3248
13 WilsonWH, Sorbara L, Figg WD, et al. Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystau-rosporine: presentation of a novel therqpeutic paradigm. Clin Cancer Res 2000; 6: 415
14 AkinagaS, Gomi K, M orimoto M, et al. Antitumor activity of UCN-01, a selective nhibitor of protein kinase C, in murine and human tumor models. Cancer Res, 1991; 51: 4888
15 Akinaga S, Nomura K, Gomi K, et al. Enhancement of antitqmor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C. Cancer Chemother Pharmacol, 1993; 32: 183
16 Wang Q, Worland PJ, Clark JL, et al. Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts cor-relaes with activation of cyclin-dependent kinases 1 and 2. Cell Growth Differ 1995; 6: 927
17 Wang S, Vrana JA, Bartimole TM, et al. Agents that down-regulate or inhibit protein kinase C cir-crnnvent resistance to 1-beta-D- arabinofuranosylcyto- sine-nduced apoptosis in human leukemia cells that overexpress Bcl-2. Mol Pharmacol, 1997; 52: 1000
18 Wang Q, Fan S, Eastman A, Worland PJ, Sausville EA, O Connor PM. UCN-01: a potent abrogator of G 2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst, 1996; 88: 956
19 Seynaeve CM, Stetler-Stevenson M, Sebers S, et al.Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res, 1993; 53: 2081
20 Courage C, Budworth J, Gescher A. Comparison of ability of protein kinase C inhibitors to arrest cell growth and to alter cellular protein kinase C localisation. Br J Cancer 1995; 71: 697
21 Budworth J, Davies R, Malkhandi J, et al. Comparison of staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug -resistant MCF-7 / Adr cells. Br J Cancer 1996; 73: 1063
22 Chen X, Lowe M, Keyomarsi K. UCN-01-mediated G1 arrest in normal but not tumor breast cells is p Rb- dependent and p53independent (Process Citation) Oncogene, 1999; 18: 5691
23 Senderowicz AM, Sausville EA. P re clinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst, 2000; 92: 376
24 Tsuchida E, Tsuchida M, Urano M. Protein kinase inhibitors flavopiridol and 7 iiydroxy-staurosporine downi’egulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood2000 Jul 15; 96(2): 393
25 Jones CB, Clements M K, Wasi S, et al. Enhancement of camptothecin-induced cytotoxicity with UCN.01 in breast cancer cells - abrogation of S’G (2) arrest. Cancer C hem other Pharmacol, 2000; 45: 252
26 Courage C, Snowden R, Gescher A. Differential effects of staurosporine analogues on cell cycle, growth and viability in A 549 cells. Br J Cancer, 1996; 74: 1199
27 Shimizu E, Zhao M R, Nakanishi H, et al.Differing effects of staurosporine and UCN-01 on RB protein phosphorylation and expression of lung cancer cell lines. Oncology, 1996; 53: 494
28 Mack PC, Gandara DR, Bowen C, et al. RB status as a determinant of response to UCN-01 in non-small cell lung carcinoma.Clin Cancer Res 1999; 5: 2596
29 Sugiyama K, Akiyama T, Shimizu M, et al. Decrease in susceptibility toward induction of apoptosis and alteration in G1 checkpoint function as determinants of resistance of human lung cancer cells against the antisignaling drug UCN-01 (7-Hydroxystaurosporine). Cancer Res, 1999; 59: 4406
30 Usuda J, Saijo N, Fukuoka K, et al.Molecular determinants of UCN -01-induced growth inhibition in human lung cancer cells. Int J Cancer, 2000; 85: 275
31 Shao RG, Cao CX, Shimizu T, et al.Abrogation of an Sphase checkpoint and potentiation of camp- tothecin cytotoxicity by 7-hydroxystaurosporine (UCN -01) in human cancer cell lines possibly influenced by p53 function. Cancer Res 1997; 57: 4029
32 Akiyama T, Shimizu M, Okabe M, et al. Differential effects o f UCN-01 stauro sporine and CGP 41 251 on cell cycle progression and CDC2’cyclin B1 regulation in A431 cells synchronized at M phase by nocodazole. Anti Cancer Drugs, 1999; 10: 67
33 McMasters RA, Wilbert TN, Jones KE, et al. Two-drug com binations that increase apoptosis and modulate bak and bcl-X (L) expression in human colon tumor cell lines transduced with herpes simplex virus thymidine kinase. Cancer Gene T her, 2000; 7: 563
34 Sugiyama K, Shimizu M, Akiyama T, et al. UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G (2) checkpoint abrogation. Int J Cancer, 2000; 85: 703
35 Pollack IF, Kawecki S, Lazo JS. Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor. J Neurosurg, 1996; 84: 1024
36 Bredel M, Pollack IF, Freund JM, et al. Protein kinase C inhibition by UCN-01 induces apoptosis in human glioma cells in a time-dependent fashion. J Neurooncol, 1999; 41: 9
37 Jiang H, Yang LY. Cell cycle checkpoint abrogator UCN-01 inhibits DNA repair: association with attenuation of the interaction of XPA and ERCC 1 nu-cleotite excision repair proteins. Cancer Res, 1999; 59: 4529
38 Akinaga S, Nomura K, Go mi K, et al. Effect of UCN01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoid carcinoma, A 431 cells. Cancer Chemother Pharmacol, 1994; 33: 273
39 Akiyama T, Yoshida T, T sujita T, et al. G 1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/ip 1/WAF1/Sdi1 in p53-iiutated human epidermoid carcinoma A431 cells. Cancer Res, 1997; 57: 1495
40 Kruger EA, Blagosklonny MV, Dixon SC, et al. UCN-01, a protein kinase C inhibitor, inhibits endothelial cell proliferation and angiogenic hypoxic response. Invasion Metastasis, 1998; 18: 209
41 Hill DL, Tillery KF, Rose LM, et al. Disposition in mice of 7-hydroxystaurosporine a protein kinase inhibitor with antitumor activity. Cancer Chemother Pharmacol, 1994; 35: 89
42 Tsuchida E, Tsuchida M, Urano M. Synergistic cytotoxicity bet ween a protein kinase C inhibitor UCN-01, and monoclonal antibody to the epidermal growth factor receptor on MDA-468 cells. Cancer Biother Radiopharn, 1997; 12: 117
43 Sausville EA, Lush RD, Headlee D, et al. Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models. Cancer Chen other Pharmacol, 1998; 42(suppl) S54
44 Kurata N, Kuwabara T, T anii H, et al. Pharm acoki-netics and pharmacodynamics of a novel protein kinase inhibitor, UCN-01. Cancer Chemother Pharma-col, 1999; 44: 12
45 Shao RG, Shimizu T, Pommier Y. 7- Hydroxystau- rosporine (UCN-01) induces apoptosis in hum an colon carcinoma and leukemia cells independently of p53. Exp Cell Res, 1997; 234: 388
46 NievesNeira W, Pommier Y. A pop to tic response to camp to thecin and 7-hydroxy staurosporine (UCN -01) in the 8 human breast cancer cell lines of the NCI Anticancer Drug Scressen Smultifactorial relationships with topoisomerase I, protein kinase C, Brl-2, p53, MDM-2 and caspase pathways. Int J Cancer, 1999; 82: 396
47 Monks A, Harris ED, Vaigro-Wolff A, et al. UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines. Invest New Drugs, 2000; 18: 95
48 Ferreira CG, Todis C, Giaccone G. p 53 and chemosensitivity. Ann Oncol, 1999; 10: 1011
49 Fan S, Deiry WS, Bae I, et al. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res, 1994; 54: 5824
50 O Connor PM, Jackman J, Jondle D, et al. Role of thep53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitts lymphoma cell lines. Cancer Res, 1993; 53: 4776
51 Hiraoka W, Vazquez N, Nieves-Neira W, et al. Role of oxygen radicals generated by NADPH oxidase in apoptosis induced in human leukemia cells. J Clin Invest, 1998; 102: 1961
52 Hsueh CT, Kelsen D, Schwartz GK. UCN-01 sup-presses thymidylate synthase gene expression and en hances 5-fluorouradl-induced apoptosis in a sequence- dependent manner. Clin Cancer Res, 1998; 4: 2201
53 Kawakami K, Futami H, T akahara J et al. UCN-01, 7-hydroxy-staurosporine, inhibits kinase activity of cyclin-lependent kinases and reduces the phospho-rylation of the retinoblastoma susceptibility gene product in A 549 human lung cancer cell line. Biochem Biophys Res Commun. 1996; 219: 778
54 Akiyama T, Sugiyama K, Shimizu M, et al. G 1 - checkpoint function including a cyclin-dependent ki- nase 2 regulatory pathway as potential determinant of 7-hydroxystaurosporine (UCN-01)- induced apop- tosis and G1-phase accumulation. Jpn J Cancer Res, 1999; 90: 1364
55 Weinert T. DNA damage and checkpoint pathways - molecular anatomy and interactions with repair. Cell, 1998; 94: 555
56 O Connor PM, Fan S. DNA damage checkpoints: implications for cancer therapy. Prog Cell Cycle Res, 1996; 2: 165
57 Bunch RT, Eastman A. Enhancement of cisplatin- induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor.Clin Cancer Res, 1996; 2: 791
58 Yu L, Orlandi L, Wang P, et al.UCN-01 abrogates G2 arrest through a Cdc2-dependent pathsay that is associated with inactivation of the Wee1Hu kinase and activation of the C dc 25C phosphatase. J Biol Chem, 1998; 273: 33455
59 Lee SI, Brown MK, Eastman A. Comparison of the efficacy of 7-hydroxystaurosporine (UCN-01) and other staurosporine analogs to abrogate cisplatin-induced cell cycle arrest in human breast cancer cell lines. Biochem Pharmacol, 1999; 58: 1713
60 Busby EC, Leistritz DF, Abraham RT, et al. The radio sensitizing agent 7-y droxy stauros porine (UCN - 01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res, 2000; 60:2108
61 Sarkaria JN, Busby EC, Tibbetts RS, et al. Inhibition of ATM and AT R kinase activities by the radio sensitizing agent, caffeine. Cancer Res, 1999; 59: 4375
62 Graves PR, Yu L, Schwarz JK, et al. The Chk 1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem, 2000; 275: 5600
63 Shao RG, Cao CX, Zhang H, et al. Replication- mediated DNA damage by cam ptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA: DNA-PK complexes. EMBO J, 1999; 18: 1397
64 Liu B, Maher RJ, Hannun YA, et al.12(S)-HETE enhancement of prostate tumor cell invasion: selective role of PKC alpha. J Natl Cancer Inst, 1994; 86: 1145
65 Timar J, Raso E, Fazakas ZS, et al.Multiple use of a signal transduction pathway in tumor cell invasion. Anticancer Res, 1996; 16: 3299
66 Szaniawska B, Gawrychowski K, Janik P. The effect of protein kinase C inhibitors on invasion of human ovary cancer cells. Neoplasma, 1998; 45: 7
67 Stam JC, Michiels F, van der Kammen RA, et al. Invasion of T-lymphoma cells: cooperation between Rho family GTPases and lysophospholipid receptor signaling. EM BO J, 1998; 17: 4066
68 Shimao Y, Nabeshima K, Inoue T, et al. TPA- enhanced motility and invasion in a highly metastatic variant (L-10) of human rectal adenocarcinoma cell line RCM-1: selective role of PKC-alpha and its inhibition by a combination of PDBu-nduced PKC dow nregulation and ant) sense oligonucleotides treatment. Clin Exp Metastasis, 1999; 17: 351
69 Hoelting T, Duh QY, Clark OH, et al. Tamoxifen antagonizes proliferation and invasion of estrogen receptor-negative metastatic follicular thyroid cancer cells via protein kinase C. Cancer Lett, 1996; 100: 89
70 Zhang W, Law RE, Hinton DR, et al. Inhibition of human malignant glioma cell motility and invasion in vitro by hypericin a potent protein kinase C inhibitor. Cancer Lett, 1997; 120: 31
71 Li H, Forstermann U. Structure-activity relationship of staurosporine analogs in regulating expression of endothelial nitricoxide synthase gene. Mol Pharmacol 2000; 57: 427
72 Yoshida S, Shimizu E, Ogura T, et al. Stimulatory effect of reconstituted basement membrane components (matrigel) on the colony formation of a panel of human lung cancer cell lines in soft agar. J Cancer Res Clin Oncol, 1997; 123: 301
73 Jiang H, Yang LY. Cell cycle checkpoint abrogator UCN-01 inhibits DNA repair: association with attenuation of the interaction of XPA and ERCC 1 nucleotide excision repair proteins. Cancer Res, 1999; 59: 4529
74 Fuse E, Tanii H, Takai K, et al. Altered pharmacokinetics of a novel anticancer drug, UCN-01, caused by specific high affinity binding to alpha1-acid glycoprotein in humans. Cancer Res, 1999; 59: 1054
75 Fuse E, Hashimoto A, Sato Net al. Physiological modeling of altered pharmacokinetics of a novel anticancer drug, UCN-01 (7-hydroxystaurosporine) caused by slow dissociation of UCN-01 from hum an alpha1-acid glycoprotein. Pharm Res, 2000; 17: 553
76 Sommers GM, Alfieri AA. Multimodality therapy: radiation and continuous concomitant cis-platinum and PKC inhibition in a cervical carcinoma model. Cancer Invest, 1998; 16: 462
77 Tsuchida E, Urano M. The effect of UCN-01 (7-hydroxystaurosporine) a potent inhibitor of protein kinase C, on fractionated radiotherapy or daily chemotherapy of a murine fibrosarcoma. Int J Radiat Oncol Biol Phys, 1997; 39: 1153 |
